The past several years have been extremely exciting in the field of bladder cancer, with checkpoint inhibitors emerging as efficacious therapies for otherwise refractory cancer. In this interview, Andrea Apolo, MD, of the National Cancer Institute, Bethesda, MD, discusses this success and how we can continue to drive this improvement forwards, with a focus on predictive biomarkers. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.
How can we continue the success of checkpoint inhibitors for bladder cancer treatment?
